NVAX May 2024 4.000 call
| Previous close | 0.8500 |
| Open | 0.8500 |
| Bid | 0.9100 |
| Ask | 1.2900 |
| Strike | 4.00 |
| Expiry date | 2024-05-31 |
| Day's range | 0.8500 - 0.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
- Reuters
UPDATE 4-Shah Capital urges Novavax shareholders to vote against three directors
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals related to executive compensation, weeks after pushing for a board shakeup at the COVID-19 vaccine maker. Shah Capital, the biotech's third-largest shareholder with a near 7.5% stake, reiterated that the company was "undervalued and continues to suffer from poor profitability". Novavax last year had raised doubts about its ability to remain in business, hurt by manufacturing snags and regulatory hurdles that delayed the entry of its protein-based vaccine to the market.
ReutersShah Capital urges Novavax shareholders to vote against three directors
Shah Capital, the biotech's third-largest shareholder with a near 7.5% stake, reiterated that the company was "undervalued and continues to suffer from poor profitability". Novavax last year had raised doubts about its ability to remain in business, hurt by manufacturing snags and regulatory hurdles that delayed the entry of its protein-based vaccine to the market. Shah Capital had previously said it plans to put forward two of its own candidates for appointment to Novavax's board, but did not formally submit any nominations.
- Reuters
CORRECTED-UPDATE 3-Novavax's top shareholder Shah Capital ramps up efforts for board shakeup
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals related to executive compensation, ramping up its efforts for a board shakeup at the COVID-19 vaccine maker. Shah Capital, which currently owns a near 7.5% stake in Novavax and is its third-largest shareholder, reiterated that the company was "undervalued and continues to suffer from poor profitability". Novavax last year had raised doubts about its ability to remain in business, hurt by manufacturing snags and regulatory hurdles that delayed the entry of its protein-based vaccine to the market.
